Novo Nordisks PIONEER I and II study, Rybelsus produced weight loss of 3.8 to 4.4 kg after 26 weeks using 14 mg of the drug.[4][5] This compares to the 5.0 to 5.3 kg loss observed in the Rybelsus arm in Lexarias Phase Ib study using 3 mg and later 7 mg of Rybelsus, suggesting that there may be features of this population that make it different from the enrolled population in the PIONEER studies and the impact of small cohort sizes
Constipation, fatigue, and gastrointestinal discomfort round out the common complaints
Mounjaro is a dual-action GLP-1/GIP medication typically prescribed to treat diabetes and shown to help people lose an average of 20% of their body weight.* A Zealthy provider will review your healthcare assessment & prescribe Mounjaro, if appropriate
Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect: What are some other side effects of this drug
Since tirzepatide already reduces appetite, most users naturally eat less at each sitting
Not for human consumption, medical, or veterinary use
